HUTCHMED (China) Limited (0013.HK)

30,700 -0,150 (-0,49%) Alla chiusura: 04:08PM HKT

HUTCHMED (China) Limited

Cheung Kong Center
48th floor 2 Queen's Road Central
Hong Kong
Hong Kong
852 2121 8200
https://www.hutch-med.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 1.988

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Chi Keung To ACGI, B.Sc., M.B.A.	Executive Chairman	664,9k	N/D	1951
Dr. Wei-Guo Su B.Sc., Ph.D.	CEO, Chief Scientific Officer & Executive Director	19,17M	N/D	1958
Mr. Chig Fung Cheng BEc, CA	CFO & Executive Director	7,53M	N/D	1967
Ms. Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.E	Company Secretary & Non-Executive Director	N/D	N/D	1952
Dr. Karen Jane Atkin	Executive VP & COO	N/D	N/D	1966
David Ng	Head of Investor Relations & Capital Strategies	N/D	N/D	N/D
Mr. Charles George Rupert Nixon	Group General Counsel	N/D	N/D	1970
Mr. Kin Hung Lee M.B.A.	Senior Vice President of Corporate Management & Communications	N/D	N/D	1977
Ms. Selina Zhang	Senior Vice President of Global Human Resources	N/D	N/D	N/D
Dr. Qingmei Wang Ph.D.	Senior Vice President of Business Development & Strategic Alliances	N/D	N/D	1963

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in HKD.

Descrizione

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Governance aziendale

L'ISS Governance QualityScore di HUTCHMED (China) Limited al 1 maggio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 4; diritti degli azionisti: 9; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.